Sunny Pharmtech Inc. (TPEX:6676)

Market Cap	2.05B
Revenue (ttm)	418.01M
Net Income (ttm)	-156.00M
Shares Out	148.76M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,977
Average Volume	166,784
Open	13.50
Previous Close	13.75
Day's Range	13.40 - 13.65
52-Week Range	12.90 - 28.35
Beta	-0.04
RSI	36.83
Earnings Date	Aug 10, 2025

About Sunny Pharmtech

Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug in Taiwan, the United States, and internationally. Its products portfolio include lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; aminocaproic acid tablets for bloo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 154
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6676

Financial Performance

In 2024, Sunny Pharmtech's revenue was 418.01 million, a decrease of -2.52% compared to the previous year's 428.83 million. Losses were -156.00 million, 146.4% more than in 2023.